74. STEMPATH: www.stempath.com

StemPath Inc. represents one of the few companies taking a traditional therapeutic drug approach to regenerative medicine. StemPath aims to become the first, pharmaceutical company specializing in therapeutic solutions that modulate the body’s natural regenerative capacity - endogenously replacing damaged tissues with new tissues - by intervention with novel small molecule and biological drugs. The company's initial focus is in cardiac and skeletal muscle myopathies. Currently at the discovery stage, StemPath is engaged in vivo proof of concept experiments and anticipates entering into preclinical testing by early 2007.

StemPath is privately held and has its headquarters based in Ottawa, Ontario. The Company has laboratory operations on the campus of the Ottawa Health Research Institute.

Regenerative medicine is an emerging multidisciplinary field that can involve biology, medicine, and engineering. It promises to revolutionize the ways we improve the health and quality of life for millions of people worldwide by restoring, maintaining, or enhancing tissue and organ function. Recent discoveries have identified various organ specific sub-populations of adult stem cells that exist within most tissues throughout the human body. It is believed that these pockets of cells are part of a naturally occurring regenerative capacity within the human body which, during times of injury, allows the body to respond to tissue damage. Stem Path’s research is focused on the molecular pathways that regulate the regenerative capacity of stem cells in both cardiac and skeletal muscle. Unlike the invasive exogenous stem cell approaches championed by many groups, StemPath scientists believe that a significant opportunity exists to exploit the naturally occurring regenerative capacity within human tissues - by designing novel therapeutics that can modulate these adult stem cells endogenously. To date, the Company has developed a patent estate pertaining to signal transduction leading to the activation and differentiation in both skeletal and cardiac stem cells. These particular pathways provide for a platform of therapeutic opportunities in both cardiac and skeletal, myopathic conditions. The Company's business focus is to develop drugs that target these pathways for cardiac and muscle wasting disease indications, namely Cancer Cachexia (muscle wasting) and Duchenne Muscular Dystrophy.

StemPath is firmly committed to providing a rewarding, challenging, and exciting place to work for it's employees. The company's growth and success is a direct result of the positive contribution of its employees' talents and energies. Our employees are encouraged to grow and advance in their careers.

StemPath Inc
501 Smyth Road, Box 511
Ottawa, Ontario
Canada
K1H 8L6

Telephone: (613) 737 8899 ext 79250
Fax: (613) 737 8399

Email: info@stempath.com